Gastric Cancer Therapeutics Market Outlook With Industry Review And Forecasts By Major Key Players - Pfizer, Eli Lilly, GlaxoSmithKline plc And Others

Survival rate for stomach cancer is greatly dependent upon the stage or phase of the disease during diagnosis. The earlier the stage of the disease progression, the higher is the survival rate. In Asia Pacific, the majority of the cases are detected at the later stage of the disease and predominantly among the geriatric population. Growth of the geriatric population in the region is leading to a proportional increase in occurrence of gastric cancer. This factor, along with growing health awareness leading to a rise in demand for early detection would fuel growth of the gastric cancer therapeutics industry over the forecast period.

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012. Gastric cancer was the fifth-most common type of cancer in the world. This epidemic has forced researchers, doctors, and governments to adopt various therapeutic treatments related to gastric cancer. An increase in investment by the companies and regulations by the government encouraging research on the same has provided significant momentum to the growth of the gastric cancer therapeutics market.

Request For A Free Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/194

Gastric cancer, also known as stomach cancer, is a type of cancer that develops within the inside layer of the stomach. Symptoms may include upper abdominal pain, yellowing of the skin, heartburn, sudden weight loss, blood in the stool, loss of appetite, and nausea, among others. This type of cancer may multiply to unaffected parts of the body mainly to the lungs, liver, the lining of the abdomen, lymph nodes, and bones. The key cause of gastric cancer is contagion by Helicobacter pylori.

Presently, the products available in the market constitutes of an extensive variety of treatment alternatives such as angiogenesis inhibitors, new chemotherapies and HER2-targeted therapy. However, demand for therapeutics that can take care of HER2-negative stomach cancer patients is high. Nevertheless, the gastric cancer market is experiencing a gradual change from generic treatment regimen to targeted therapies. This will further enhance the growth of the global gastric cancer therapeutics market.

Some of the companies operating in the gastric cancer therapeutics market in the current scenario are Pfizer, Eli Lilly, GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA, AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La Roche Ltd. Some of the other companies operating in the market are Ono Pharmaceutical/Bristol-Myers Squibb, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, and Merck.

Download the Free PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/194

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.